Benzinga | Aug 5, 2020 06:53AM EDT

Needham Maintains Buy on GenMark Diagnostics, Raises Price Target to $22

Needham analyst Mike Matson maintains GenMark Diagnostics (NASDAQ:GNMK) with a Buy and raises the price target from $19 to $22.